ReviewFrontiers in immunology2026
Tertiary lymphoid structures in breast cancer: formation, immune functions and clinical implications.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and challenges of immunotherapy in advancedFrontiers in oncology · 2026Article
- The heterogeneous and dynamic immune-tumor interface in breast cancer.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tertiary lymphoid structures (TLS) are ectopic lymphoid aggregates that arise in non-lymphoid tissues under chronic inflammatory conditions and during tumor development. Although TLS have often been associated with a favorable prognosis and enhanced therapeutic responsiveness, their biological and clinical significance in breast cancer is highly heterogeneous and cannot be adequately captured by a simple TLS-positive versus TLS-negative classification. In this review, we summarize the structural organization and developmental stages of TLS, with an emphasis on the functional relevance of maturation, including germinal center formation. We further discuss current concepts regarding the mechanisms driving TLS initiation and maturation, including stromal activation, chemokine-guided immune cell recruitment, and high endothelial venule-mediated lymphocyte trafficking. In addition, we examine the major dimensions of TLS heterogeneity in breast cancer, including differences in maturity, spatial location, molecular subtype, and immune cellular composition, and discuss how these variables shape antitumor, immunoregulatory, and context-dependent TLS functions. We also evaluate the current approaches for TLS identification and classification, highlighting the strengths and limitations of histopathology, immunophenotyping, multiplex imaging, and transcriptomic inference. Finally, we discuss the prognostic and predictive relevance of TLS in breast cancer, the barriers limiting its clinical translation, and key priorities for future research. Overall, TLS status represents a promising but context-dependent biomarker and potential therapeutic intermediate whose interpretation requires standardized classification and a deeper mechanistic understanding.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.